Shkreli, the former chief executive officer of
New York Attorney General
Shkreli is already serving a seven-year sentence for securities fraud committed while running two hedge funds, though the same drug -- Daraprim -- is at the center of both cases.
Vyera, then known as Turing Pharmaceuticals, was launched by Shkreli in 2015. That’s when he acquired Daraprim, a once-affordable anti-infective used to treat a sometimes-deadly parasitic infection, from the only existing supplier. Shkreli then raised the price from $17.50 to $750 per tablet.
Cote found that Shkreli made illegal agreements with generic drug makers to delay introduction of cheaper versions of the drug after he jacked up the price.
“Shkreli does not dispute that it was his intention to impede generic pharmaceutical companies from launching competitive products that would threaten the price of Daraprim,” the judge wrote. “The plaintiffs have shown that the restraints Vyera implemented succeeded in doing just that.”
Last month, Vyera and another former chief executive officer,
(Updates with detail from the litigation)
To contact the reporters on this story:
To contact the editors responsible for this story:
Jim Silver, Anthony Lin
© 2022 Bloomberg L.P. All rights reserved. Used with permission.